Streetbeat News

Stock Prices

ADIL

HEPA

NKGN

VAXX

In Monday's pre-market session, health care stocks showed significant movement. Adial Pharmaceuticals (ADIL) and NKGen Biotech (NKGN) led the gainers with over 30% increases in their stock prices, while Vaxxinity (VAXX) and Hepion Pharmaceuticals (HEPA) were among the top losers, with VAXX stock dropping over 60%. The movements were attributed to various factors, including recent earnings reports for some companies.

Portfolio Pulse from Benzinga Insights

April 22, 2024 | 12:07 pm

CSLR

MKFG

NMHI

SOAR

In Monday's pre-market session, there were notable movements in the industrials sector stocks. Complete Solaria, Volato Group, AERWINS Technologies, FiscalNote Holdings, CDT Environmental, and Energy Vault Holdings saw significant gains, while Markforged Holding, Nature's Miracle Holding, Swvl Hldgs, Expion360, 1847 Holdings, and Jet AI experienced declines.

Portfolio Pulse from Benzinga Insights

April 22, 2024 | 12:06 pm

FRES

Fresh2 Group Ltd. (NASDAQ:FRES), a B2B e-commerce and supply chain management company in the food industry, received a delinquency notice from Nasdaq for not filing its Annual Report on time. The company has 60 days to submit a compliance plan to avoid delisting.

Portfolio Pulse from Benzinga Newsdesk

April 22, 2024 | 12:05 pm

WASH

Washington Trust Bancorp (NASDAQ:WASH) reported Q1 2024 earnings of $0.64 per share, surpassing the $0.45 estimate, with sales of $31.665M also beating the $31.500M forecast. However, both earnings and sales saw a decrease compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

April 22, 2024 | 12:04 pm

AILE

ANL

CDE

IAUX

INFA

MNDR

TSLA

Tesla, Inc. (TSLA) shares fell 3.6% in pre-market trading after announcing a $2,000 price cut for its U.S. electric-vehicle lineups, affecting its shares and those of other companies. iLearningEngines, Inc. (AILE), Adlai Nortye Ltd. (ANL), Li Auto Inc. (LI), Mobile-health Network Solutions (MNDR), Coeur Mining, Inc. (CDE), i-80 Gold Corp. (IAUX), and Informatica Inc. (INFA) also saw declines in pre-market trading due to various factors including market reactions to Tesla's price cut, pullbacks in precious metals prices, and acquisition talks.

Portfolio Pulse from Avi Kapoor

April 22, 2024 | 12:04 pm

CPNG

TAST

Two consumer discretionary stocks, Carrols Restaurant Group, Inc (TAST) and Coupang, Inc. (CPNG), are highlighted as overbought with RSI values above 70, signaling potential short-term performance concerns. TAST's stock rose after a 13D filing showed a 3.27% stake by Gabelli Funds, while CPNG plans to raise its membership fees by 58%, affecting its stock negatively.

Portfolio Pulse from Avi Kapoor

April 22, 2024 | 12:03 pm

ELAB

Elevai Labs, Inc. (ELAB) has entered into a distribution agreement with ILIA International Ltd. for the distribution of its products in Taiwan. This strategic move aims to expand ELAB's market presence in Asia.

Portfolio Pulse from Benzinga Newsdesk

April 22, 2024 | 12:03 pm

OCGN

Ocugen (NASDAQ:OCGN) has received consistent bullish ratings from 4 analysts over the past quarter, with a recent update showing an average 12-month price target of $6.5, marking a 44.44% increase from the previous target of $4.50. Analysts from Chardan Capital and HC Wainwright & Co. have raised their price targets, indicating a positive outlook on the company's performance. Ocugen's financial performance shows a significant revenue growth of 142.6% over the past 3 months, despite a lower market capitalization and challenges in net margin, ROE, and ROA compared to industry averages.

Portfolio Pulse from Benzinga Insights

April 22, 2024 | 12:01 pm

ADIL

Adial Pharmaceuticals Inc (NASDAQ:ADIL) has been granted a US patent (number 11957664) for a combination of its proprietary genetic diagnostic and its lead investigational drug, AD04, for treating alcohol use disorder (AUD) and other drug dependencies such as opioid use disorder (OUD). This patent strengthens Adial's intellectual property portfolio, covering specific genotypes for targeted treatment. The addressable market for these treatments in the U.S. is estimated at $40 billion. Additionally, Adial has previously received a patent for AD04 targeting the serotonin transporter gene for potential OUD treatment and published positive clinical results and safety profiles for AD04.

Portfolio Pulse from Vandana Singh

April 22, 2024 | 12:00 pm

KEX

Kirby Corp (NYSE:KEX) has received mixed analyst ratings over the past three months, with a recent shift towards a more bullish outlook. The latest evaluations from four analysts show an increase in the 12-month price target to an average of $116.00, up from $100.00, indicating a positive sentiment shift. Kirby, a leading domestic tank barge operator, has shown notable revenue growth of 9.45% as of December 31, 2023, but faces challenges in profitability and efficiency, with below-average net margin, ROE, and ROA.

Portfolio Pulse from Benzinga Insights

April 22, 2024 | 12:00 pm